{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:51:26Z","timestamp":1793055086914,"version":"4.5.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enhancer of zeste homolog 2 (EZH2) is frequently upregulated in prostate cancer (PCa) and further increased in castration-resistant prostate cancer (CRPC), a lethal state characterized by profound immune dysfunction. However, EZH2-associated immune programs in bulk cohorts and their corresponding cell-type\u2013specific features in single-cell RNA sequencing (scRNA-seq) data have not been systematically delineated in advanced PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated bulk RNA-seq and scRNA-seq to map EZH2-associated transcriptional and immune features in PCa. In bulk cohorts (TCGA-PRAD and an independent metastatic CRPC cohort), we quantified EZH2 expression, clinical outcomes, and immune-signature enrichment. Immune-modulated differentially expressed genes (IMDEGs) were defined by intersecting EZH2-associated differential expression with correlations to Treg\/TAM-related signature scores, and were used for NMF-based immune subtyping and penalized Cox modeling with validation. In scRNA-seq cohorts (GSE264573 and an independent CRPC cohort), malignant epithelial cells were inferred by copy-number alteration profiles, EZH2^high versus EZH2^low malignant programs were characterized, T-cell subsets were quantified, and tumor\u2013Treg communication was inferred using CellPhoneDB as hypothesis-generating predictions. For perturbation, the EZH2 inhibitor tazemetostat was evaluated in the CRPC-relevant C42 cell line with H3K27me3 readouts and transcriptomic profiling, with key changes validated by RT\u2013qPCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across bulk cohorts, higher EZH2 expression was associated with adverse clinical outcomes and increased enrichment of immunosuppressive signatures, including Treg- and TAM-related programs. IMDEG-based NMF subtyping identified patient groups with distinct immune states, and an IMDEG-derived risk score stratified prognosis. Single-cell profiling revealed elevated EZH2 in CRPC malignant cells and Tregs; EZH2^high malignant cells exhibited a proliferative transcriptional state accompanied by reduced expression of immune-related programs. Predicted tumor\u2013Treg interaction patterns were stronger in CRPC and positively associated with EZH2 expression. In C42 cells, tazemetostat reduced H3K27me3 and induced coordinated transcriptional changes, including upregulation of immune- and inflammation-associated genes such as TIMP3, PLCG2, and SOCS3, validated by RT\u2013qPCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This multi-layer integrative analysis suggests that EZH2 is associated with proliferative malignant states and immunosuppressive microenvironment features in advanced PCa, including Treg-linked crosstalk. Transcriptomic profiling following EZH2 inhibition supports modulation of these programs by EZH2-targeted perturbation, while functional and causal mechanisms warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1725097","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T06:29:28Z","timestamp":1770100168000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrative bulk and single-cell transcriptomics link EZH2 to immunosuppressive programs and tumor\u2013Treg crosstalk in castration-resistant prostate cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Xing","family":"Xiong","sequence":"first","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Data Analysis, Biosalt Inc","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixiao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Affiliated Hospital of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.09.011","article-title":"Castration-resistant prostate cancer: adaptive responses in the androgen axis","volume":"40","author":"Egan","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071064","article-title":"Immunotherapy in prostate cancer: from a \u201cCold\u201d Tumor to a \u201cHot\u201d Prospect","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B6","article-title":"Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy","volume":"10","author":"Wang","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1181051","article-title":"Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis","volume":"14","author":"Noori","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060826","article-title":"Role of tumor microenvironment in prostate cancer immunometabolism","volume":"15","author":"Wang","year":"2025","journal-title":"Biomolecules"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.05.009","article-title":"Regulatory interactions between RNA and polycomb repressive complex 2","volume":"55","author":"Cifuentes-Rojas","year":"2014","journal-title":"Mol Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"188700","DOI":"10.1016\/j.bbcan.2022.188700","article-title":"EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy","volume":"1877","author":"Sun","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.01.007","article-title":"The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation","volume":"42","author":"DuPage","year":"2015","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00185-w","article-title":"EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer","volume":"2","author":"Morel","year":"2021","journal-title":"Nat Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2016.1208872","article-title":"Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors","volume":"15","author":"Wassef","year":"2016","journal-title":"Cell Cycle"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081778","article-title":"The immunotherapy and immunosuppressive signaling in therapy-resistant prostate cancer","volume":"10","author":"Xu","year":"2022","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"326470","DOI":"10.1101\/326470","article-title":"The UCSC Xena platform for public and private cancer genomics data visualization and interpretation","author":"Goldman","year":"2018","journal-title":"biorxiv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100141","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12943-025-02360-4","article-title":"Targeting PERP promotes anti-tumor immunity in HNSCC by regulating tumor immune microenvironment and metabolic homeostasis","volume":"24","author":"Wang","year":"2025","journal-title":"Mol Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","article-title":"Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen\u2013targeted therapies","volume":"121","author":"Zaidi","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41467-022-28803-w","article-title":"Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data","volume":"13","author":"Ianevski","year":"2022","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac757","article-title":"GSEApy: a comprehensive package for performing gene set enrichment analysis in Python","volume":"39","author":"Fang","year":"2023","journal-title":"Bioinformatics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0292-x","article-title":"CellPhoneDB: inferring cell\u2013cell communication from combined expression of multi-subunit ligand\u2013receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat Protoc"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2217\/epi-2023-0374","article-title":"Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response","volume":"16","author":"Fischetti","year":"2024","journal-title":"Epigenomics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41423-021-00742-4","article-title":"Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy","volume":"19","author":"Huppert","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21175983","article-title":"Roles of proteoglycans and glycosaminoglycans in cancer development and progression","volume":"21","author":"Wei","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623137","article-title":"Inflammation-associated drug resistance and tumor growth in TNBC","volume":"16","author":"Hassan","year":"2025","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01982-4","article-title":"Going beyond Polycomb: EZH2 functions in prostate cancer","volume":"40","author":"Park","year":"2021","journal-title":"Oncogene"},{"key":"B38","doi-asserted-by":"publisher","first-page":"155992","DOI":"10.1016\/j.prp.2025.155992","article-title":"EZH2 regulatory roles in cancer immunity and immunotherapy","volume":"270","author":"Mortezaee","year":"2025","journal-title":"Pathol Res Pract"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/genes14030580","article-title":"SERPINF1 mediates tumor progression and stemness in glioma","volume":"14","author":"Song","year":"2023","journal-title":"Genes (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2174\/1871520620666200731161810","article-title":"FOXM1-dependent transcriptional regulation of EZH2 induces proliferation and progression in prostate cancer","volume":"21","author":"Tian","year":"2021","journal-title":"Anticancer Agents Med Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-021-00716-0","article-title":"Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses","volume":"102","author":"Shui","year":"2022","journal-title":"Lab Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1781-6","article-title":"A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer","volume":"65","author":"Noguchi","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/life13020333","article-title":"Impact of immune cells in the tumor microenvironment of prostate cancer metastasis","volume":"13","author":"Messex","year":"2023","journal-title":"Life (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M804835200","article-title":"Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner","volume":"283","author":"Saegusa","year":"2008","journal-title":"J Biol Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030393","article-title":"The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells","volume":"7","author":"Shin","year":"2012","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1725097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T06:29:29Z","timestamp":1770100169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1725097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2026.1725097"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1725097","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1725097"}}